Enovis Corp (ENOV)vsNovartis AG ADR (NVS)
ENOV
Enovis Corp
$23.44
+4.22%
HEALTHCARE · Cap: $1.35B
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2417% more annual revenue ($56.58B vs $2.25B). NVS leads profitability with a 23.9% profit margin vs -52.7%. ENOV appears more attractively valued with a PEG of 1.90. ENOV earns a higher WallStSmart Score of 56/100 (C).
ENOV
Buy56
out of 100
Grade: C
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.0%
Fair Value
$60.01
Current Price
$23.44
$36.57 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 153.1% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
2.6% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ENOV
The strongest argument for ENOV centers on Price/Book, EPS Growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ENOV
The primary concerns for ENOV are PEG Ratio, Revenue Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
ENOV profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
ENOV carries more volatility with a beta of 1.59 — expect wider price swings.
ENOV is growing revenue faster at 2.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
ENOV scores higher overall (56/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Enovis Corp
HEALTHCARE · MEDICAL DEVICES · USA
Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?